Eduardo J Mortani Barbosa1, Maarten Lanclus2, Wim Vos2, Cedric Van Holsbeke2, William De Backer3, Jan De Backer2, James Lee4. 1. Perelman School of Medicine, University of Pennsylvania, Departments of Radiology and Medicine, 3400 Spruce Street, Philadelphia, PA 19104. Electronic address: Eduardo.Barbosa@uphs.upenn.edu. 2. FLUIDDA nv, Kontich, Belgium. 3. University Hospital Antwerp, Department of Respiratory Medicine, Edegem, Belgium. 4. Perelman School of Medicine, University of Pennsylvania, Departments of Radiology and Medicine, 3400 Spruce Street, Philadelphia, PA 19104.
Abstract
RATIONALE AND OBJECTIVES: Long-term survival after lung transplantation (LTx) is limited by bronchiolitis obliterans syndrome (BOS), defined as a sustained decline in forced expiratory volume in the first second (FEV1) not explained by other causes. We assessed whether machine learning (ML) utilizing quantitative computed tomography (qCT) metrics can predict eventual development of BOS. MATERIALS AND METHODS: Paired inspiratory-expiratory CT scans of 71 patients who underwent LTx were analyzed retrospectively (BOS [n = 41] versus non-BOS [n = 30]), using at least two different time points. The BOS cohort experienced a reduction in FEV1 of >10% compared to baseline FEV1 post LTx. Multifactor analysis correlated declining FEV1 with qCT features linked to acute inflammation or BOS onset. Student t test and ML were applied on baseline qCT features to identify lung transplant patients at baseline that eventually developed BOS. RESULTS: The FEV1 decline in the BOS cohort correlated with an increase in the lung volume (P = .027) and in the central airway volume at functional residual capacity (P = .018), not observed in non-BOS patients, whereas the non-BOS cohort experienced a decrease in the central airway volume at total lung capacity with declining FEV1 (P = .039). Twenty-three baseline qCT parameters could significantly distinguish between non-BOS patients and eventual BOS developers (P < .05), whereas no pulmonary function testing parameters could. Using ML methods (support vector machine), we could identify BOS developers at baseline with an accuracy of 85%, using only three qCT parameters. CONCLUSIONS: ML utilizing qCT could discern distinct mechanisms driving FEV1 decline in BOS and non-BOS LTx patients and predict eventual onset of BOS. This approach may become useful to optimize management of LTx patients.
RATIONALE AND OBJECTIVES: Long-term survival after lung transplantation (LTx) is limited by bronchiolitis obliterans syndrome (BOS), defined as a sustained decline in forced expiratory volume in the first second (FEV1) not explained by other causes. We assessed whether machine learning (ML) utilizing quantitative computed tomography (qCT) metrics can predict eventual development of BOS. MATERIALS AND METHODS: Paired inspiratory-expiratory CT scans of 71 patients who underwent LTx were analyzed retrospectively (BOS [n = 41] versus non-BOS [n = 30]), using at least two different time points. The BOS cohort experienced a reduction in FEV1 of >10% compared to baseline FEV1 post LTx. Multifactor analysis correlated declining FEV1 with qCT features linked to acute inflammation or BOS onset. Student t test and ML were applied on baseline qCT features to identify lung transplant patients at baseline that eventually developed BOS. RESULTS: The FEV1 decline in the BOS cohort correlated with an increase in the lung volume (P = .027) and in the central airway volume at functional residual capacity (P = .018), not observed in non-BOSpatients, whereas the non-BOS cohort experienced a decrease in the central airway volume at total lung capacity with declining FEV1 (P = .039). Twenty-three baseline qCT parameters could significantly distinguish between non-BOSpatients and eventual BOS developers (P < .05), whereas no pulmonary function testing parameters could. Using ML methods (support vector machine), we could identify BOS developers at baseline with an accuracy of 85%, using only three qCT parameters. CONCLUSIONS: ML utilizing qCT could discern distinct mechanisms driving FEV1 decline in BOS and non-BOSLTxpatients and predict eventual onset of BOS. This approach may become useful to optimize management of LTxpatients.
Authors: Husham Sharifi; Yu Kuang Lai; Henry Guo; Mita Hoppenfeld; Zachary D Guenther; Laura Johnston; Theresa Brondstetter; Laveena Chhatwani; Mark R Nicolls; Joe L Hsu Journal: Chest Date: 2020-04-25 Impact factor: 10.262
Authors: Neta Gotlieb; Amirhossein Azhie; Divya Sharma; Ashley Spann; Nan-Ji Suo; Jason Tran; Ani Orchanian-Cheff; Bo Wang; Anna Goldenberg; Michael Chassé; Heloise Cardinal; Joseph Paul Cohen; Andrea Lodi; Melanie Dieude; Mamatha Bhat Journal: NPJ Digit Med Date: 2022-07-11
Authors: Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny Journal: Transplant Cell Ther Date: 2021-06-10
Authors: Jeremy A Balch; Daniel Delitto; Patrick J Tighe; Ali Zarrinpar; Philip A Efron; Parisa Rashidi; Gilbert R Upchurch; Azra Bihorac; Tyler J Loftus Journal: Front Immunol Date: 2021-09-16 Impact factor: 7.561